Cover Image
市場調查報告書

前列腺肥大症:開發中產品分析

Benign Prostatic Hyperplasia - Pipeline Review, H2 2016

出版商 Global Markets Direct 商品編碼 232805
出版日期 內容資訊 英文 128 Pages
訂單完成後即時交付
價格
Back to Top
前列腺肥大症:開發中產品分析 Benign Prostatic Hyperplasia - Pipeline Review, H2 2016
出版日期: 2016年11月16日 內容資訊: 英文 128 Pages
簡介

前列腺是包圍男性尿道的腺體,功能主要是分泌前列腺液(精液的部分成分),前列腺肥大症(BPH)便是該腺體的非癌性肥大疾病,症狀有尿勢低、排尿後滴尿、排尿疼痛、夜間頻尿、腹壓排尿等。BPH的治療有手術和投藥等。

本報告涵括全球前列腺肥大症治療藥的開發平台,提供您目前開發平台狀況和最新趨勢,藥物簡介,主要企業及開發中的產品檢討等資訊,為您概述為以下內容。

簡介

  • 調查範圍

前列腺肥大症概要

治療藥的開發

  • 開發中產品的概要
  • 開發中產品比較分析

前列腺肥大症:企業開發中的治療藥

前列腺肥大症:大學/機關研究中的治療藥

前列腺肥大症:開發中產品概況

  • 後期階段的產品
  • 臨床階段的產品
  • 初期階段的產品
  • 開發階段不明的產品

前列腺肥大症:企業開發中的產品

前列腺肥大症:大學/機關研究中的產品

前列腺肥大症的治療藥的開發企業

  • AndroScience Corporation
  • Aphios Corporation
  • Ausio Pharmaceuticals, LLC
  • BCWorld Pharm Co. Ltd.
  • Chong Kun Dang Pharmaceutical Corp.
  • Dongkook Pharmaceutical Co., Ltd.
  • Euroscreen S.A.
  • Hanmi Pharmaceuticals, Co. Ltd.
  • Jeil Pharmaceutical Co., Ltd.
  • 科研製藥
  • Meiji Seika Pharma Co., Ltd.
  • Mezzion Pharma Co. Ltd.
  • Monosol Rx, LLC
  • Nymox Pharmaceutical Corporation
  • Ono Pharmaceutical Co., Ltd.
  • Sihuan Pharmaceutical Holdings Group Ltd.
  • SK Chemicals Co., Ltd.
  • SOM Innovation Biotech SL
  • Sophiris Bio, Inc.
  • Yungjin Pharm. Co., Ltd.

前列腺肥大症:治療藥的評估

  • 單劑產品
  • 組合產品
  • 標的別
  • 各作用機制
  • 各給藥途徑
  • 各分子類型

藥物簡介

前列腺肥大症:最近的開發平台趨勢

前列腺肥大症:暫停中的計劃

前列腺肥大症:開發中止的產品

前列腺肥大症:產品開發的里程碑

  • 主要消息和新聞稿

附錄

本網頁內容可能與最新版本有所差異。詳細情況請與我們聯繫。

目錄
Product Code: GMDHC8679IDB

Summary

Global Markets Direct's latest Pharmaceutical and Healthcare disease pipeline guide Benign Prostatic Hyperplasia - Pipeline Review, H2 2016, provides an overview of the Benign Prostatic Hyperplasia (Male Health) pipeline landscape.

Benign Prostatic Hyperplasia (BPH) is a non-cancerous enlargement of the prostate, a small gland that encircles the urethra in males and produces a fluid that makes up part of semen. Symptoms include decreased strength of the urine stream, dribbling after urination, pain during urination, waking at night to urinate, difficulty starting a urine stream. Treatment options for BPH include surgery and medications.

Report Highlights

Global Markets Direct's Pharmaceutical and Healthcare latest pipeline guide Benign Prostatic Hyperplasia - Pipeline Review, H2 2016, provides comprehensive information on the therapeutics under development for Benign Prostatic Hyperplasia (Male Health), complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The guide covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases.

The Benign Prostatic Hyperplasia (Male Health) pipeline guide also reviews of key players involved in therapeutic development for Benign Prostatic Hyperplasia and features dormant and discontinued projects. The guide covers therapeutics under Development by Companies /Universities /Institutes, the molecules developed by Companies in Phase III, Phase II, Phase I, IND/CTA Filed, Preclinical, Discovery and Unknown stages are 10, 5, 6, 1, 8, 1 and 1 respectively. Similarly, the Universities portfolio in Preclinical and Discovery stages comprises 2 and 1 molecules, respectively.Benign Prostatic Hyperplasia.

Benign Prostatic Hyperplasia (Male Health) pipeline guide helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage. The guide is built using data and information sourced from Global Markets Direct's proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.

Note: Certain content / sections in the pipeline guide may be removed or altered based on the availability and relevance of data.

Scope

  • The pipeline guide provides a snapshot of the global therapeutic landscape of Benign Prostatic Hyperplasia (Male Health).
  • The pipeline guide reviews pipeline therapeutics for Benign Prostatic Hyperplasia (Male Health) by companies and universities/research institutes based on information derived from company and industry-specific sources.
  • The pipeline guide covers pipeline products based on several stages of development ranging from pre-registration till discovery and undisclosed stages.
  • The pipeline guide features descriptive drug profiles for the pipeline products which comprise, product description, descriptive licensing and collaboration details, R&D brief, MoA & other developmental activities.
  • The pipeline guide reviews key companies involved in Benign Prostatic Hyperplasia (Male Health) therapeutics and enlists all their major and minor projects.
  • The pipeline guide evaluates Benign Prostatic Hyperplasia (Male Health) therapeutics based on mechanism of action (MoA), drug target, route of administration (RoA) and molecule type.
  • The pipeline guide encapsulates all the dormant and discontinued pipeline projects.
  • The pipeline guide reviews latest news related to pipeline therapeutics for Benign Prostatic Hyperplasia (Male Health)

Reasons to buy

  • Procure strategically important competitor information, analysis, and insights to formulate effective R&D strategies.
  • Recognize emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage.
  • Find and recognize significant and varied types of therapeutics under development for Benign Prostatic Hyperplasia (Male Health).
  • Classify potential new clients or partners in the target demographic.
  • Develop tactical initiatives by understanding the focus areas of leading companies.
  • Plan mergers and acquisitions meritoriously by identifying key players and it's most promising pipeline therapeutics.
  • Formulate corrective measures for pipeline projects by understanding Benign Prostatic Hyperplasia (Male Health) pipeline depth and focus of Indication therapeutics.
  • Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope.
  • Adjust the therapeutic portfolio by recognizing discontinued projects and understand from the know-how what drove them from pipeline.

Table of Contents

  • Table of Contents
    • List of Tables
    • List of Figures
  • Introduction
    • Global Markets Direct Report Coverage
  • Benign Prostatic Hyperplasia Overview
  • Therapeutics Development
    • Pipeline Products for Benign Prostatic Hyperplasia - Overview
    • Pipeline Products for Benign Prostatic Hyperplasia - Comparative Analysis
  • Benign Prostatic Hyperplasia - Therapeutics under Development by Companies
  • Benign Prostatic Hyperplasia - Therapeutics under Investigation by Universities/Institutes
  • Benign Prostatic Hyperplasia - Pipeline Products Glance
    • Late Stage Products
    • Clinical Stage Products
    • Early Stage Products
    • Unknown Stage Products
  • Benign Prostatic Hyperplasia - Products under Development by Companies
  • Benign Prostatic Hyperplasia - Products under Investigation by Universities/Institutes
  • Benign Prostatic Hyperplasia - Companies Involved in Therapeutics Development
    • Addex Therapeutics Ltd
    • AndroScience Corporation
    • Aphios Corporation
    • BCWorld Pharm Co. Ltd.
    • Biolab Farmaceutica Ltda
    • Chong Kun Dang Pharmaceutical Corp.
    • Dongkook Pharmaceutical Co., Ltd.
    • Hanmi Pharmaceuticals, Co. Ltd.
    • Health Ever Bio-Tech Co., Ltd.
    • Jeil Pharmaceutical Co., Ltd.
    • Kaken Pharmaceutical Co., Ltd.
    • MEI Pharma, Inc.
    • Meiji Seika Pharma Co., Ltd.
    • Mezzion Pharma Co. Ltd.
    • Monosol Rx LLC
    • Nymox Pharmaceutical Corporation
    • Ogeda SA
    • Ono Pharmaceutical Co., Ltd.
    • SK Chemicals Co., Ltd.
    • SOM Biotech SL
    • Sophiris Bio, Inc.
    • Vantia Therapeutics
    • XuanZhu Pharma Co Ltd
    • Yungjin Pharm. Co., Ltd.
  • Benign Prostatic Hyperplasia - Therapeutics Assessment
    • Assessment by Monotherapy Products
    • Assessment by Combination Products
    • Assessment by Target
    • Assessment by Mechanism of Action
    • Assessment by Route of Administration
    • Assessment by Molecule Type
  • Drug Profiles
    • (dutasteride + tadalafil) - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • (solifenacin succinate + tamsulosin hydrochloride) - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • (tadalafil + tamsulosin hydrochloride) - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • ADX-68692 - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • ASC-JM.X2 - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • AUS-131 - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • BCWPE-004 - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • BL-214 - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • ESN-364 - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • fadanafil - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • fedovapagon - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • fexapotide triflutate - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • HCP-1303 - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • HIP-1402 - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • KKM-1202 - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • L-1AD3 - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • MCS-2 - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • NCE-403 - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • ONO-8430506 - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • S-40542 - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • Small Molecules to Inhibit Steroidal 5-Alpha Reductase for Benign Prostatic Hyperplasia - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • SOM-2391 - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • SOM-2393 - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • Sperol - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • Synthetic Peptide to Antagonize GPR54 for Womens Health, Male Health and Oncology - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • tadalafil - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • talaporfin sodium - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • tamsulosin hydrochloride CR - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • tamsulosin hydrochloride DR - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • tamsulosin hydrochloride SR - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • tertomotide - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • topsalysin - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • udenafil - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • YBH-1603 - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • YOB-1604 - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
  • Benign Prostatic Hyperplasia - Dormant Projects
  • Benign Prostatic Hyperplasia - Discontinued Products
  • Benign Prostatic Hyperplasia - Product Development Milestones
    • Featured News & Press Releases
      • Sep 20, 2016: Addex collaborators publish new data on negative allosteric modulator ADX68692
      • May 05, 2016: Sophiris Bio To Present Topsalysin Phase 3 Data from Positive PLUS-1 Study as a Late Breaking Poster During the 111th American Urological Association Annual Meeting
      • Apr 01, 2015: Nymox Announces Phase 3 BPH Studies
      • Dec 15, 2014: Sophiris Bio Reports Administrative Interim Analysis for the "PLUS-1" Phase 3 Trial of PRX302 for Benign Prostatic Hyperplasia
      • Nov 02, 2014: Nymox NX-1207 BPH Pivotal Phase 3 U.S. Studies NX02-0017 and NX02-0018 Fail to Meet Primary Efficacy Endpoints
      • Sep 02, 2014: Sophiris Bio Reports Completion of Enrollment in the "PLUS-1" Phase 3 Trial of PRX302 for Benign Prostatic Hyperplasia
      • Jul 22, 2014: Nymox Announces Positive Efficacy Results in Phase 3 Repeat Injection Trial of NX-1207 for BPH
      • Jul 15, 2014: Nymox Announces Completion of Enrollment for Second BPH Re-Injection Study
      • Jun 17, 2014: Nymox Reports Positive Update on Nerve Sparing and Sexual Function Preservation in Men Treated With NX-1207
      • Jun 11, 2014: Nymox Reports Positive New Safety Study Data for Phase 3 BPH Drug
      • May 08, 2014: Nymox Announces Completion of Second Pivotal Phase 3 NX-1207 Trial for BPH
      • Nov 11, 2013: Nymox Reports Update and Positive Safety Data for Phase 3 NX02-0022 Reinjection Study of NX-1207 for BPH
      • Oct 28, 2013: Sophiris Announces First Patients Dosed in the PLUS-1 Phase 3 Trial of PRX302 for Benign Prostatic Hyperplasia
      • Aug 22, 2013: Nymox Reports Positive Results of Safety Monitoring Committee Review of NX02-0018 Phase 3 Trial
      • Jul 11, 2013: Nymox Reports Positive Safety Monitoring Committee Results for Pivotal NX02-0017 Phase 3 Trial
  • Appendix
    • Methodology
    • Coverage
    • Secondary Research
    • Primary Research
    • Expert Panel Validation
    • Contact Us
    • Disclaimer

List of Tables

  • Number of Products under Development for Benign Prostatic Hyperplasia, H2 2016
  • Number of Products under Development for Benign Prostatic Hyperplasia - Comparative Analysis, H2 2016
  • Number of Products under Development by Companies, H2 2016
  • Number of Products under Investigation by Universities/Institutes, H2 2016
  • Comparative Analysis by Late Stage Development, H2 2016
  • Comparative Analysis by Clinical Stage Development, H2 2016
  • Comparative Analysis by Early Stage Development, H2 2016
  • Comparative Analysis by Unknown Stage Development, H2 2016
  • Products under Development by Companies, H2 2016
  • Products under Development by Companies, H2 2016 (Contd..1)
  • Products under Investigation by Universities/Institutes, H2 2016
  • Benign Prostatic Hyperplasia - Pipeline by Addex Therapeutics Ltd, H2 2016
  • Benign Prostatic Hyperplasia - Pipeline by AndroScience Corporation, H2 2016
  • Benign Prostatic Hyperplasia - Pipeline by Aphios Corporation, H2 2016
  • Benign Prostatic Hyperplasia - Pipeline by BCWorld Pharm Co. Ltd., H2 2016
  • Benign Prostatic Hyperplasia - Pipeline by Biolab Farmaceutica Ltda, H2 2016
  • Benign Prostatic Hyperplasia - Pipeline by Chong Kun Dang Pharmaceutical Corp., H2 2016
  • Benign Prostatic Hyperplasia - Pipeline by Dongkook Pharmaceutical Co., Ltd., H2 2016
  • Benign Prostatic Hyperplasia - Pipeline by Hanmi Pharmaceuticals, Co. Ltd., H2 2016
  • Benign Prostatic Hyperplasia - Pipeline by Health Ever Bio-Tech Co., Ltd., H2 2016
  • Benign Prostatic Hyperplasia - Pipeline by Jeil Pharmaceutical Co., Ltd., H2 2016
  • Benign Prostatic Hyperplasia - Pipeline by Kaken Pharmaceutical Co., Ltd., H2 2016
  • Benign Prostatic Hyperplasia - Pipeline by MEI Pharma, Inc., H2 2016
  • Benign Prostatic Hyperplasia - Pipeline by Meiji Seika Pharma Co., Ltd., H2 2016
  • Benign Prostatic Hyperplasia - Pipeline by Mezzion Pharma Co. Ltd., H2 2016
  • Benign Prostatic Hyperplasia - Pipeline by Monosol Rx LLC, H2 2016
  • Benign Prostatic Hyperplasia - Pipeline by Nymox Pharmaceutical Corporation, H2 2016
  • Benign Prostatic Hyperplasia - Pipeline by Ogeda SA, H2 2016
  • Benign Prostatic Hyperplasia - Pipeline by Ono Pharmaceutical Co., Ltd., H2 2016
  • Benign Prostatic Hyperplasia - Pipeline by SK Chemicals Co., Ltd., H2 2016
  • Benign Prostatic Hyperplasia - Pipeline by SOM Biotech SL, H2 2016
  • Benign Prostatic Hyperplasia - Pipeline by Sophiris Bio, Inc., H2 2016
  • Benign Prostatic Hyperplasia - Pipeline by Vantia Therapeutics, H2 2016
  • Benign Prostatic Hyperplasia - Pipeline by XuanZhu Pharma Co Ltd, H2 2016
  • Benign Prostatic Hyperplasia - Pipeline by Yungjin Pharm. Co., Ltd., H2 2016
  • Assessment by Monotherapy Products, H2 2016
  • Assessment by Combination Products, H2 2016
  • Number of Products by Stage and Target, H2 2016
  • Number of Products by Stage and Mechanism of Action, H2 2016
  • Number of Products by Stage and Route of Administration, H2 2016
  • Number of Products by Stage and Molecule Type, H2 2016
  • Benign Prostatic Hyperplasia - Dormant Projects, H2 2016
  • Benign Prostatic Hyperplasia - Dormant Projects (Contd..1), H2 2016
  • Benign Prostatic Hyperplasia - Dormant Projects (Contd..2), H2 2016
  • Benign Prostatic Hyperplasia - Discontinued Products, H2 2016

List of Figures

  • Number of Products under Development for Benign Prostatic Hyperplasia, H2 2016
  • Number of Products under Development for Benign Prostatic Hyperplasia - Comparative Analysis, H2 2016
  • Number of Products under Development by Companies, H2 2016
  • Number of Products under Investigation by Universities/Institutes, H2 2016
  • Comparative Analysis by Clinical Stage Development, H2 2016
  • Comparative Analysis by Early Stage Products, H2 2016
  • Assessment by Monotherapy Products, H2 2016
  • Assessment by Combination Products, H2 2016
  • Number of Products by Top 10 Targets, H2 2016
  • Number of Products by Stage and Top 10 Targets, H2 2016
  • Number of Products by Top 10 Mechanism of Actions, H2 2016
  • Number of Products by Stage and Top 10 Mechanism of Actions, H2 2016
  • Number of Products by Routes of Administration, H2 2016
  • Number of Products by Stage and Routes of Administration, H2 2016
  • Number of Products by Molecule Types, H2 2016
  • Number of Products by Stage and Molecule Types, H2 2016
Back to Top